Evaluation of efficacy of intralesional Inj. Vitamin D versus intralesional Inj. Acyclovir in the treatment of recalcitrant cutaneous warts: A randomised clinical trial.

Patients with cutaneous warts attending the Outpatient Department of Dermatology were enrolled after obtaining informed written consent with complete history taking and thorough cutaneous examination

Clinico‑demographic details of participants were recorded and clinical,  images were taken at baseline and at each follow‑up visit i.e at 2nd ,4th ,6th, and 8th week .

All patients fulfilling the inclusion criteria will be categorized into two groups depending on the treatment they received, namely, Group A (intralesional Vit D) and Group B (intralesional acyclovir) (n=20 per group ) 1

Group A : Vitamin D3 (0.2mL, 15mg/dl)   injected into the base of the warts after injecting with lidocaine (0.2mL, 15mg/dl).

Group B : Intralesional injection of acyclovir (70 mg/ml), at a dose of 0.1 ml, injected into the base of each wart.

Repeated two weeks apart for a maximum of four sessions or until complete clearance, whichever occureds earlier.

Patients were further followed up for a period of 6  months after treatment completion.

Clinical response documented by recording the decrease in number and size of  lesions at each visit i.e., at 2 weekly intervals for 4 sessions and 3 months after the last injection.

The reduction in the size and number of warts classified the response to treatment into four grades based on the Visual Analogue Scale (VAS) score